Literature DB >> 24895178

Safety signal detection: the relevance of literature review.

Helena Pontes1, Mallorie Clément, Victoria Rollason.   

Abstract

Adverse drug reactions (ADRs) represent an important risk for patients and have a significant economic impact on health systems. ADRs are the fifth most common cause of hospital death, with a burden estimated at 197,000 deaths per year in the EU. This has a societal cost of <euro>79 billion per year. Because of this strong impact in public health, regulatory authorities (RAs) worldwide are implementing new pharmacovigilance legislation to promote and protect public health by reducing the burden of ADRs through the detection of safety signals. Although, traditionally, signal detection activities have mainly been performed based on spontaneous reporting from healthcare professionals and national health RAs, the new pharmacovigilance legislation underlines the relevance of other sources of information (such as scientific literature) for the evaluation of the benefit-risk balance of a certain product. This review aims to highlight the relevance of periodic scientific literature screening in the safety signal detection process. The authors present four practical examples where a safety signal that was detected from a literature report had an impact on the lifecycle of a drug. In addition, based on practical experience of the screening of medical and scientific literature for safety purposes, this article analyses the requirements of the new pharmacovigilance guidelines on literature screening and highlights the need for the implementation of a literature review procedure and the main challenges encountered when performing literature screening for safety aspects.

Entities:  

Mesh:

Year:  2014        PMID: 24895178     DOI: 10.1007/s40264-014-0180-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  15 in total

1.  Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.

Authors:  F J de Abajo; L A Rodríguez; D Montero
Journal:  BMJ       Date:  1999-10-23

Review 2.  The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.

Authors:  J A Arnaiz; X Carné; N Riba; C Codina; J Ribas; A Trilla
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

Review 3.  Handsearching versus electronic searching to identify reports of randomized trials.

Authors:  S Hopewell; M Clarke; C Lefebvre; R Scherer
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

4.  Guidelines for submitting adverse event reports for publication.

Authors:  William N Kelly; Felix M Arellano; Joanne Barnes; Ulf Bergman; Ralph I Edwards; Alina M Fernandez; Stephen B Freedman; David I Goldsmith; Kui A Huang; Judith K Jones; Rachel McLeay; Nicholas Moore; Rosie H Stather; Thierry Trenque; William G Troutman; Eugene van Puijenbroek; Frank Williams; Robert P Wise
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Omeprazole and refractory hypomagnesaemia.

Authors:  N Shabajee; E J Lamb; I Sturgess; R W Sumathipala
Journal:  BMJ       Date:  2008-07-10

6.  Fatal aplastic anaemia associated with nifedipine.

Authors:  J R Laporte; L Ibáñez; E Ballarín; E Pérez; X Vidal
Journal:  Lancet       Date:  1998-08-22       Impact factor: 79.321

7.  Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells.

Authors:  K Kitano; C N Abboud; D H Ryan; S G Quan; G C Baldwin; D W Golde
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

8.  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors:  H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

9.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

10.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  W O Spitzer; M A Lewis; L A Heinemann; M Thorogood; K D MacRae
Journal:  BMJ       Date:  1996-01-13
View more
  13 in total

1.  A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.

Authors:  Alexandra C Pacurariu; Preciosa M Coloma; Anja van Haren; Georgy Genov; Miriam C J M Sturkenboom; Sabine M J M Straus
Journal:  Drug Saf       Date:  2014-12       Impact factor: 5.606

2.  Pharmacovigilance: empowering healthcare professionals and patients.

Authors:  Stephane Steurbaut; Yolande Hanssens
Journal:  Int J Clin Pharm       Date:  2014-09-05

3.  Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.

Authors:  Stella Stergiopoulos; Mortiz Fehrle; Patrick Caubel; Louise Tan; Louise Jebson
Journal:  Pharmaceut Med       Date:  2019-12

4.  Analyzing search behavior of healthcare professionals for drug safety surveillance.

Authors:  David J Odgers; Rave Harpaz; Alison Callahan; Gregor Stiglic; Nigam H Shah
Journal:  Pac Symp Biocomput       Date:  2015

5.  Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use.

Authors:  Rebecca N Jerome; Meghan Morrison Joly; Nan Kennedy; Jana K Shirey-Rice; Dan M Roden; Gordon R Bernard; Kenneth J Holroyd; Joshua C Denny; Jill M Pulley
Journal:  Drug Saf       Date:  2020-06       Impact factor: 5.606

6.  Impact of literature reports on drug safety signals.

Authors:  Bartlomiej Ochyra; Maciej Szewczyk; Adam Przybylkowski
Journal:  Wien Klin Wochenschr       Date:  2020-05-26       Impact factor: 1.704

7.  A time-indexed reference standard of adverse drug reactions.

Authors:  Rave Harpaz; David Odgers; Greg Gaskin; William DuMouchel; Rainer Winnenburg; Olivier Bodenreider; Anna Ripple; Ana Szarfman; Alfred Sorbello; Eric Horvitz; Ryen W White; Nigam H Shah
Journal:  Sci Data       Date:  2014-11-11       Impact factor: 6.444

8.  Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.

Authors:  Samantha Lane; Elizabeth Lynn; Saad Shakir
Journal:  BMJ Open       Date:  2018-01-23       Impact factor: 2.692

9.  Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era.

Authors:  Renato Ferreira-da-Silva; Inês Ribeiro-Vaz; Manuela Morato; Jorge Junqueira Polónia
Journal:  Int J Clin Pharm       Date:  2021-06-02

10.  A curated and standardized adverse drug event resource to accelerate drug safety research.

Authors:  Juan M Banda; Lee Evans; Rami S Vanguri; Nicholas P Tatonetti; Patrick B Ryan; Nigam H Shah
Journal:  Sci Data       Date:  2016-05-10       Impact factor: 6.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.